About F3 Platform Biologics
F3 is a team of business and science professionals who specialize in solving the problems inherent in low dose radiation exposure. We are the world’s foremost experts in cytoprotectants and radioprotectants.
In particular, we are uniquely focused on inhibiting or minimizing the stochastic effects of radiation: those for which increasing doses or exposures result in a higher probability of an effect such as genetic mutations and cancers.
We hold a worldwide exclusive license from the University of Chicago and a series of granted and pending patents to develop applications within certain markets for Amifostine. We plan to bring this science to market in new and meaningful ways that prevent illness, save lives, and enhance quality of life on a global scale.
We have a history of proven success in the research and development of biotechnology solutions and are led by a team of experts in delivering successful business outcomes that have demonstrated substantial value for individuals, investors and partners.
